CraniUS' mission is to invent and engineer world-class technology to define the future of diagnostics and treatments for neurosurgical patients with brain disease. CAUTION – The NeuroPASS device is an investigational device limited by Federal (or United States) law to investigational use and is not available for commercial distribution.
Location: United States
Total raised: $20M
Investors 1
| Date | Name | Website |
| 07.05.2025 | Johns Hopk... | ventures.j... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 02.02.2026 | Series B | $20M | - |
Mentions in press and media 2
| Date | Title | Description |
| 02.02.2026 | CraniUS Therapeutics Inks $20M Series B Round | BALTIMORE, MD, CraniUS Therapeutics LLC, a privately held neurotechnology company, announced it has raised $20 million in Series B financing. >> Click here for more funding data on CraniUS >> To export CraniUS funding data to P... |
| 28.01.2026 | CraniUS Therapeutics Raises $20M in Series B Funding | CraniUS Therapeutics LLC, a Baltimore, MD-based privately held neurotechnology company, raised $20M in Series B funding. The raise followed its $20M Series A round in 2022. The Series B included $19M from private investors and $1M in non-di... |